Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc (A) delivers cutting-edge analytical instruments and laboratory solutions for scientific advancement across biopharmaceutical, diagnostic, and environmental sectors. This page provides investors and industry professionals with a centralized source for all official company announcements and market-relevant developments.
Access real-time updates on Agilent's financial performance, strategic partnerships, product innovations, and regulatory milestones. Our curated news collection includes earnings releases, executive leadership updates, R&D breakthroughs, and industry event coverage—all essential for tracking the company's impact on life sciences and laboratory technology.
Key focus areas include advancements in genomic research tools, sustainability initiatives in lab operations, and cross-sector collaborations driving scientific discovery. Bookmark this page to stay informed about Agilent's evolving role in enabling precision medicine, environmental testing, and next-generation materials analysis.
Agilent (NYSE: A) reported Q4 FY2025 revenue $1.86B, up 9.4% reported and up 7.2% on a core basis versus Q4 2024, with GAAP EPS of $1.53 (up 25% YoY) and non-GAAP EPS of $1.59 (up 9% YoY). Full FY2025 revenue was $6.95B, up 6.7% reported; FY2025 GAAP EPS was $4.57 and non-GAAP EPS was $5.59. Management provided FY2026 guidance of $7.3B–$7.4B revenue (up 5%–7% reported) and non-GAAP EPS $5.86–$6.00; Q1 FY2026 revenue guidance is $1.79B–$1.82B with non-GAAP EPS $1.35–$1.38.
Crawford & Company (NYSE: CRD-A and CRD-B) announced a leadership transition: CEO Rohit Verma will step down effective December 31, 2025, and CFO W. Bruce Swain Jr. will become interim president & CEO and board member effective January 1, 2026. Holly Boudreau will succeed Swain as CFO effective January 1, 2026. Swain brings more than 30 years at Crawford and will focus on executing strategic plans and empowering employees. Verma served as CEO since May 2020 and joined Crawford in 2017. The company describes the transition as occurring from a position of financial strength with a global leadership team in place.
Agilent (NYSE: A) announced a quarterly cash dividend of 25.5 cents per share. The dividend is payable on Jan. 28, 2026 to shareholders of record at the close of business on Jan. 6, 2026. The company said timing and amounts of future dividends remain subject to the board of directors’ determination and approval.
Agilent reported $6.51 billion in revenue for fiscal year 2024 and employs approximately 18,000 people worldwide. The release includes customary forward-looking statement language about risks and uncertainties related to the dividend program.
Agilent Technologies (NYSE: A) announced the Altura Ultra Inert HPLC columns, a new product line aimed at biotherapeutics analysis including peptide GLP-1 and oligonucleotide workflows. The release highlights faster conditioning, improved peak shape, enhanced sensitivity, and a fully inert sample flow path designed for demanding QC and development labs.
Agilent claims up to 2x sensitivity, 3x signal-to-noise ratio, and, when paired with the Agilent 1290 Infinity III Bio LC, up to 30x higher peak area; an external test cited a ~30% sensitivity increase and reduced peak tailing on acidic peptides.
Agilent (NYSE: A) will participate in Citi’s 2025 Global Healthcare Conference on Dec. 4, 2025. Chief Enterprise Transformation Officer Tom Callihan and Head of Investor Relations Tejas Savant will take part in a fireside chat from 9:00 to 9:45 a.m. EDT in Miami.
A live audio webcast and replay will be available on Agilent’s investor relations website. Agilent reported $6.51 billion revenue in fiscal year 2024 and employs approximately 18,000 people worldwide.
Lunit (KRX:328130.KQ) and Agilent (NYSE:A) announced a nonexclusive collaboration on Sept 22, 2025 to co-develop AI-powered companion diagnostic (CDx) solutions for complex biomarker assays.
The partnership will combine Lunit's AI algorithms and Agilent's tissue-based diagnostic assays, initially targeting research and clinical-trial use to improve biomarker accuracy and support pharma CDx development. Lunit noted its FDA-cleared Lunit INSIGHT suite is used at over 7,000 medical institutions in more than 65 countries.
TORM (NASDAQ: TRMD A) increased share capital on Nov 14, 2025 by 970,646 A-shares following exercise of Restricted Share Units (RSUs), corresponding to a nominal USD 9,706.46.
Of the new shares, 963,146 were subscribed in cash at DKK 0.07 per A-share and 7,500 at DKK 140.2 per share. The issuance was carried out without pre-emption rights. After the increase, share capital amounts to USD 1,013,185.03 divided into 101,318,501 A-shares, plus one B-share and one C-share. New shares are ordinary, carry dividend rights as of issuance, and are expected to be listed on Nasdaq Copenhagen.
TORM plc (A) reported director share transactions by CEO Jacob Balslev Meldgaard related to exercise of restricted share units in November 2025.
The exercises occurred 12 November 2025 and 14 November 2025, totaling 585,473 shares (ISIN GB00BZ3CNK81) with an aggregated value of DKK 11,961,321.62. The transactions were executed outside a trading venue. Contact for the filing is Head of Investor Relations Mikael Bo Larsen.
Agilent (NYSE: A) awarded an Agilent Research Catalyst (ARC) grant to the University of California, Davis on behalf of Professor Marie Heffern on November 12, 2025.
The award funds research using Agilent instrumentation (8900 ICP-QQQ, 6546 Q-TOF LC/MS, Infinity II LC) to study metal–peptide interactions in incretin-based therapeutics (GLP-1 receptor agonists). The project will apply LC-ICP-MS, native MS, and high-resolution peptide mapping to assess effects on drug stability, formulation, and bioactivity, aiming to build a predictive framework to inform formulation strategies and reduce degradation.
TORM plc (NASDAQ: TRMD / TRMD A) completed a capital increase of 2,395,426 A-shares (nominal USD 23,954.26) on Nov 12, 2025 related to delivery of one LR2 vessel and exercise of Restricted Share Units (RSUs).
Key items: 748,569 shares were issued to settle a USD 17.0m allocated loan note for the 2010-built LR2 (USD 22.71 per A-share). 1,646,857 A-shares were issued on RSU exercises (1,558,790 at DKK 0.07 and 88,067 at DKK 140.2). New shares are subject to a 40-day lock-up with Regulation S resale exceptions.
Post-increase share capital: USD 1,003,478.57 divided into 100,347,855 A-shares, one B-share and one C-share.
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
